Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

NCT03784222 is registered in ClinicalTrials.gov with Marubeni Pharmaceuticals (Suzhou) Co., Ltd. as lead sponsor.

NCT NCT03784222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03784222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients
Lead sponsor
Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Phase
Phase 4
Overall status
Terminated
Start date
January 22, 2019
Completion date
November 22, 2022
Enrollment
102 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

blonanserin, cognition function, first episode schizophrenia, social function